A citation-based method for searching scientific literature

Laurent Castéra, Valentin Harter, Etienne Muller, Sophie Krieger, Nicolas Goardon, Agathe Ricou, Antoine Rousselin, Germain Paimparay, Angelina Legros, Olivia Bruet, Céline Quesnelle, Florian Domin, Chankannira San, Baptiste Brault, Robin Fouillet, Caroline Abadie, Odile Béra, Pascaline Berthet, Thierry Frébourg, Dominique Vaur. Genet Med 2018
Times Cited: 33







List of co-cited articles
353 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
Andrew Tutt, Holly Tovey, Maggie Chon U Cheang, Sarah Kernaghan, Lucy Kilburn, Patrycja Gazinska, Julie Owen, Jacinta Abraham, Sophie Barrett, Peter Barrett-Lee,[...]. Nat Med 2018
295
6

Description and analysis of genetic variants in French hereditary breast and ovarian cancer families recorded in the UMD-BRCA1/BRCA2 databases.
Sandrine Caputo, Louisa Benboudjema, Olga Sinilnikova, Etienne Rouleau, Christophe Béroud, Rosette Lidereau. Nucleic Acids Res 2012
58
6

Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. N Engl J Med 2012
6

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Mark Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine Tung, Anne Armstrong,[...]. N Engl J Med 2017
6

Genetic dissection of the BRCA2 promoter and transcriptional impact of DNA variants.
Eugenia Fraile-Bethencourt, Alberto Valenzuela-Palomo, Beatriz Díez-Gómez, Mar Infante, Mercedes Durán, Germán Marcos, Enrique Lastra, Susana Gómez-Barrero, Eladio A Velasco. Breast Cancer Res Treat 2018
5
40

Molding BRCA2 function through its interacting partners.
Juan S Martinez, Céline Baldeyron, Aura Carreira. Cell Cycle 2015
15
13

A Dominantly Inherited 5' UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian Cancer.
D Gareth R Evans, Elke M van Veen, Helen J Byers, Andrew J Wallace, Jamie M Ellingford, Glenda Beaman, Javier Santoyo-Lopez, Timothy J Aitman, Diana M Eccles, Fiona I Lalloo,[...]. Am J Hum Genet 2018
31
6

Identification of fifteen novel germline variants in the BRCA1 3'UTR reveals a variant in a breast cancer case that introduces a functional miR-103 target site.
Brooke L Brewster, Francesca Rossiello, Juliet D French, Stacey L Edwards, Ming Wong, Ania Wronski, Phillip Whiley, Nic Waddell, Xiaowei Chen, Betsy Bove,[...]. Hum Mutat 2012
40
6

Functional Analysis of BARD1 Missense Variants in Homology-Directed Repair of DNA Double Strand Breaks.
Cindy Lee, Tapahsama Banerjee, Jessica Gillespie, Amanda Ceravolo, Matthew R Parvinsmith, Lea M Starita, Stanley Fields, Amanda E Toland, Jeffrey D Parvin. Hum Mutat 2015
20
10

BARD1 is necessary for ubiquitylation of nucleosomal histone H2A and for transcriptional regulation of estrogen metabolism genes.
Mikaela D Stewart, Elena Zelin, Abhinav Dhall, Tom Walsh, Esha Upadhyay, Jacob E Corn, Champak Chatterjee, Mary-Claire King, Rachel E Klevit. Proc Natl Acad Sci U S A 2018
17
11


The BARD1 Cys557Ser variant and breast cancer risk in Iceland.
Simon N Stacey, Patrick Sulem, Oskar T Johannsson, Agnar Helgason, Julius Gudmundsson, Jelena P Kostic, Kristleifur Kristjansson, Thora Jonsdottir, Helgi Sigurdsson, Jon Hrafnkelsson,[...]. PLoS Med 2006
46
6


PALB2/FANCN: recombining cancer and Fanconi anemia.
Marc Tischkowitz, Bing Xia. Cancer Res 2010
122
6

Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women.
William D Foulkes, Parviz Ghadirian, Mohammed Reza Akbari, Nancy Hamel, Sylvie Giroux, Nelly Sabbaghian, Andrew Darnel, Robert Royer, Aletta Poll, Eve Fafard,[...]. Breast Cancer Res 2007
102
6

Penetrance analysis of the PALB2 c.1592delT founder mutation.
Hannele Erkko, James G Dowty, Jenni Nikkilä, Kirsi Syrjäkoski, Arto Mannermaa, Katri Pylkäs, Melissa C Southey, Kaija Holli, Anne Kallioniemi, Arja Jukkola-Vuorinen,[...]. Clin Cancer Res 2008
76
6

A recurrent mutation in PALB2 in Finnish cancer families.
Hannele Erkko, Bing Xia, Jenni Nikkilä, Johanna Schleutker, Kirsi Syrjäkoski, Arto Mannermaa, Anne Kallioniemi, Katri Pylkäs, Sanna-Maria Karppinen, Katrin Rapakko,[...]. Nature 2007
309
6

Comprehensive sequencing of PALB2 in patients with breast cancer suggests PALB2 mutations explain a subset of hereditary breast cancer.
Priscilla H Fernandes, Jennifer Saam, Jenny Peterson, Elisha Hughes, Rajesh Kaldate, Shelly Cummings, Aaron Theisen, Sonia Chen, Jeffrey Trost, Benjamin B Roa. Cancer 2014
20
10

Germline mutations in the PALB2 gene are population specific and occur with low frequencies in familial breast cancer.
Heide Hellebrand, Christian Sutter, Ellen Honisch, Eva Gross, Barbara Wappenschmidt, Christian Schem, Helmut Deissler, Nina Ditsch, Verena Gress, Marion Kiechle,[...]. Hum Mutat 2011
41
6

Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study.
Eleanor Fewings, Alexey Larionov, James Redman, Mae A Goldgraben, James Scarth, Susan Richardson, Carole Brewer, Rosemarie Davidson, Ian Ellis, D Gareth Evans,[...]. Lancet Gastroenterol Hepatol 2018
41
6

PALB2 self-interaction controls homologous recombination.
Rémi Buisson, Jean-Yves Masson. Nucleic Acids Res 2012
35
6

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
M William Audeh, James Carmichael, Richard T Penson, Michael Friedlander, Bethan Powell, Katherine M Bell-McGuinn, Clare Scott, Jeffrey N Weitzel, Ana Oaknin, Niklas Loman,[...]. Lancet 2010
932
6

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Andrew Tutt, Mark Robson, Judy E Garber, Susan M Domchek, M William Audeh, Jeffrey N Weitzel, Michael Friedlander, Banu Arun, Niklas Loman, Rita K Schmutzler,[...]. Lancet 2010
6

Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.
Stan B Kaye, Jan Lubinski, Ursula Matulonis, Joo Ern Ang, Charlie Gourley, Beth Y Karlan, Amit Amnon, Katherine M Bell-McGuinn, Lee-May Chen, Michael Friedlander,[...]. J Clin Oncol 2012
323
6

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
Peter C Fong, David S Boss, Timothy A Yap, Andrew Tutt, Peijun Wu, Marja Mergui-Roelvink, Peter Mortimer, Helen Swaisland, Alan Lau, Mark J O'Connor,[...]. N Engl J Med 2009
6

Ovarian cancer.
Gordon C Jayson, Elise C Kohn, Henry C Kitchener, Jonathan A Ledermann. Lancet 2014
937
6

Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.
Valérie Bonadona, Bernard Bonaïti, Sylviane Olschwang, Sophie Grandjouan, Laetitia Huiart, Michel Longy, Rosine Guimbaud, Bruno Buecher, Yves-Jean Bignon, Olivier Caron,[...]. JAMA 2011
576
6

TP53 mutations in human cancers: origins, consequences, and clinical use.
Magali Olivier, Monica Hollstein, Pierre Hainaut. Cold Spring Harb Perspect Biol 2010
850
6


Hallmarks of 'BRCAness' in sporadic cancers.
Nicholas Turner, Andrew Tutt, Alan Ashworth. Nat Rev Cancer 2004
6

Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2.
Lindsey E Minion, Jill S Dolinsky, Dana M Chase, Charles L Dunlop, Elizabeth C Chao, Bradley J Monk. Gynecol Oncol 2015
64
6

Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.
Magali Olivier, David E Goldgar, Nayanta Sodha, Hiroko Ohgaki, Paul Kleihues, Pierre Hainaut, Rosalind A Eeles. Cancer Res 2003
291
6

A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer.
Paz Polak, Jaegil Kim, Lior Z Braunstein, Rosa Karlic, Nicholas J Haradhavala, Grace Tiao, Daniel Rosebrock, Dimitri Livitz, Kirsten Kübler, Kent W Mouw,[...]. Nat Genet 2017
206
6

Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13.
R Wooster, S L Neuhausen, J Mangion, Y Quirk, D Ford, N Collins, K Nguyen, S Seal, T Tran, D Averill. Science 1994
6

Association of Mismatch Repair Mutation With Age at Cancer Onset in Lynch Syndrome: Implications for Stratified Surveillance Strategies.
Neil A J Ryan, Julie Morris, Kate Green, Fiona Lalloo, Emma R Woodward, James Hill, Emma J Crosbie, D Gareth Evans. JAMA Oncol 2017
59
6

Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
Ranjit Manchanda, Shreeya Patel, Vladimir S Gordeev, Antonis C Antoniou, Shantel Smith, Andrew Lee, John L Hopper, Robert J MacInnis, Clare Turnbull, Susan J Ramus,[...]. J Natl Cancer Inst 2018
73
6

Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study.
Adam N Rosenthal, Lindsay S M Fraser, Susan Philpott, Ranjit Manchanda, Matthew Burnell, Philip Badman, Richard Hadwin, Ivana Rizzuto, Elizabeth Benjamin, Naveena Singh,[...]. J Clin Oncol 2017
69
6

Global cancer statistics, 2012.
Lindsey A Torre, Freddie Bray, Rebecca L Siegel, Jacques Ferlay, Joannie Lortet-Tieulent, Ahmedin Jemal. CA Cancer J Clin 2015
6

Multigene panels in Ashkenazi Jewish patients yield high rates of actionable mutations in multiple non-BRCA cancer-associated genes.
Melissa K Frey, Gabriella Sandler, Rachel Sobolev, Sarah H Kim, Rachelle Chambers, Rebecca Y Bassett, Jessica Martineau, Katherine J Sapra, Leslie Boyd, John P Curtin,[...]. Gynecol Oncol 2017
14
14

Common variations in BARD1 influence susceptibility to high-risk neuroblastoma.
Mario Capasso, Marcella Devoto, Cuiping Hou, Shahab Asgharzadeh, Joseph T Glessner, Edward F Attiyeh, Yael P Mosse, Cecilia Kim, Sharon J Diskin, Kristina A Cole,[...]. Nat Genet 2009
214
6

Analysis of large mutations in BARD1 in patients with breast and/or ovarian cancer: the Polish population as an example.
Katarzyna Klonowska, Magdalena Ratajska, Karol Czubak, Alina Kuzniacka, Izabela Brozek, Magdalena Koczkowska, Marcin Sniadecki, Jaroslaw Debniak, Dariusz Wydra, Magdalena Balut,[...]. Sci Rep 2015
21
9

Whole-exome sequencing identifies rare pathogenic variants in new predisposition genes for familial colorectal cancer.
Clara Esteban-Jurado, Maria Vila-Casadesús, Pilar Garre, Juan José Lozano, Anna Pristoupilova, Sergi Beltran, Jenifer Muñoz, Teresa Ocaña, Francesc Balaguer, Maria López-Cerón,[...]. Genet Med 2015
63
6


Lifetime cancer risks in individuals with germline PTEN mutations.
Min-Han Tan, Jessica L Mester, Joanne Ngeow, Lisa A Rybicki, Mohammed S Orloff, Charis Eng. Clin Cancer Res 2012
421
6

BARD1 variants are not associated with breast cancer risk in Australian familial breast cancer.
Kylie L Gorringe, David Y H Choong, Jane E Visvader, Geoffrey J Lindeman, Ian G Campbell. Breast Cancer Res Treat 2008
18
11

Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers.
T H Thai, F Du, J T Tsan, Y Jin, A Phung, M A Spillman, H F Massa, C Y Muller, R Ashfaq, J M Mathis,[...]. Hum Mol Genet 1998
140
6

Common non-synonymous polymorphisms in the BRCA1 Associated RING Domain (BARD1) gene are associated with breast cancer susceptibility: a case-control analysis.
Xiang Huo, Zhibin Hu, Xiangjun Zhai, Yan Wang, Shui Wang, Xuechen Wang, Jianwei Qin, Wenseng Chen, Guangfu Jin, Jiyong Liu,[...]. Breast Cancer Res Treat 2007
20
10

Germline mutations of the BRCA1-associated ring domain (BARD1) gene in breast and breast/ovarian families negative for BRCA1 and BRCA2 alterations.
Chiara Ghimenti, Elisa Sensi, Silvano Presciuttini, Isa Maura Brunetti, PierFranco Conte, Generoso Bevilacqua, Maria A Caligo. Genes Chromosomes Cancer 2002
81
6

BARD1 nonsense variant c.1921C>T in a patient with recurrent breast cancer.
Jennifer Gass, Madeline Tatro, Patrick Blackburn, Stephanie Hines, Paldeep S Atwal. Clin Case Rep 2017
4
50

Germline RECQL mutations are associated with breast cancer susceptibility.
Cezary Cybulski, Jian Carrot-Zhang, Wojciech Kluźniak, Barbara Rivera, Aniruddh Kashyap, Dominika Wokołorczyk, Sylvie Giroux, Javad Nadaf, Nancy Hamel, Shiyu Zhang,[...]. Nat Genet 2015
111
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.